Defence Minister Rajnath Singh will release the first batch of Anti Covid drug 2DG through video conferencing this morning. The drug has been developed by DRDO's Institute of Nuclear Medicine and Allied Sciences (INMAS) in collaboration with Dr Reddy's Laboratories.
Sources reports that clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence. Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from COVID-19.
Pursuing Prime Minister Narendra Modi’s call for preparedness against the pandemic, DRDO took the initiative of developing anti-COVID therapeutic application of 2-DG. Being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
The drug comes in powder form in sachet, which is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique. The drug is expected to save precious lives due to the mechanism of operation of the drug in infected cells. It also reduces the hospital stay of COVID-19 patients.